Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals

Simply Wall St.04-07

Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625933024?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","is_english":true,"pubTime":"2026-04-07 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625933024","market":"us","top_or_hot":-1,"title":"Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/assessing-regeneron-pharmaceuticals-regn-valuation-after-fda\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 15:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/assessing-regeneron-pharmaceuticals-regn-valuation-after-fda><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/assessing-regeneron-pharmaceuticals-regn-valuation-after-fda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0689472784.USD","symbol_name":"安联收益及增长基金Cl AM AT Acc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/assessing-regeneron-pharmaceuticals-regn-valuation-after-fda","article_id":"2625933024","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/assessing-regeneron-pharmaceuticals-regn-valuation-after-fda","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625933024","pubTimestamp":1775546531,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment schedules for eligible patients.\nSee our latest analysis for Regeneron Pharmaceuticals.\nAt a share price of $763.04, Regeneron has a 1 year total shareholder return of 33.94%, while its year to date share price return is slightly negative. This suggests that longer term momentum has been strong...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4083":"家庭装潢零售","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","BK4504":"桥水持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4588":"碎股","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4550":"红杉资本持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LABU":"三倍做多标普生物-Direxion","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","REGN":"再生元制药公司","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","HD":"家得宝","BK4581":"高盛持仓","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LU0882574055.USD":"富达全球健康医疗A ACC"},"translate_title":"FDA批准延长EYLEA HD给药间隔后评估再生元制药(REGN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5,"HD":1.5,"LABU":1.5},"content_text":"Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment schedules for eligible patients. See our latest analysis for Regeneron Pharmaceuticals. At a share price of $763.04, Regeneron has a 1 year total shareholder return of 33.94%, while its year to date share price return is slightly negative. This suggests that longer term momentum has been strong even as recent trading has been more muted around the EYLEA HD decision and other pipeline updates. If this kind of healthcare breakthrough has your attention, it could be a useful moment to see what else is moving in vision and treatment technology by checking out 37 healthcare AI stocks With REGN trading at $763.04, sitting on a 34% 1 year total return and screens showing both an intrinsic discount and a gap to analyst targets, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 12.7% Undervalued The most followed valuation narrative currently pegs Regeneron’s fair value at $873.78 versus the last close at $763.04, framing the stock as modestly undervalued and linking that gap to how EYLEA, Dupixent and the broader pipeline perform over time.  Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.  Read the complete narrative. Curious what kind of revenue path, profit margins and valuation multiple need to align for that fair value to make sense? The core narrative relies on mid teens earnings growth assumptions, an improved margin profile over time, and a premium P/E relative to the wider biotech group. The exact mix of those inputs is where the story becomes more detailed. Result: Fair Value of $873.78 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on EYLEA facing ongoing competition and pricing pressure, as well as on heavy R&D and manufacturing spend ultimately translating into commercially successful drugs rather than margin strain. Find out about the key risks to this Regeneron Pharmaceuticals narrative. Another Angle On Valuation The narrative fair value of $873.78 suggests modest undervaluation, but the current 17.4x P/E tells a different story. It is higher than the US Biotechs average of 16.2x, yet below both the peer average of 23x and a fair ratio of 25.3x. That mix points to both valuation risk and potential upside. The question is which signal investors choose to put more weight on. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:REGN P/E Ratio as at Apr 2026Next Steps With sentiment leaning cautiously optimistic so far, it makes sense to act while the details are fresh and test the thesis against your own expectations by checking the 2 key rewards. Looking for more investment ideas? If Regeneron has sharpened your interest, this is the moment to broaden your watchlist and spot other opportunities before they move out of reach.  Target long term compounding potential by scanning for quality names trading below their estimated worth through the 62 high quality undervalued stocks. Strengthen your income stream by reviewing companies with higher yields and resilient payouts using the 13 dividend fortresses. Prioritise resilience by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (40 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625933024","isCrawlerRequest":true}